JME Group Associates Inc

Biotech · Private

Oral enzyme replacement therapy using recombinant human acid alpha-glucosidase (GAA) produced in transgenic tobacco plants, administered as whole seeds for treatment of Pompe disease

Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
1 granted · 0 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Oral-ERT of Pompe Disease with Tobacco Seed-Derived Recombinant Acid Maltase$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2746AAVantgarde——
2747APIS THERAPEUTICS, LLC——
2748Abvance Therapeutics——
2749JME Group Associates Inc——
2750FELIX BIOTECHNOLOGY INC——
2751Small Molecule PPI Mimics LLC——
2752LUMEN BIOSCIENCE, INC.—$50M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 1

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.